AI summary

100% confidence

MES research with climate-geographic focus on geographic, technology, economic. Human milk oligosaccharides (HMOs) are complex nonnutritive sugars present in human milk. These sugars possess prebiotic...

Generated by MESSAI extraction pipeline · review against source PDF

Extraction

Reported parameters

1 extracted value

View extracted values

No 3D model is mapped to this paper yet. Parameter ranges above still place reported values on the literature distribution.

Abstract

Human milk oligosaccharides (HMOs) are complex nonnutritive sugars present in human milk. These sugars possess prebiotic, immunomodulatory, and antagonistic properties towards pathogens and therefore are important for the health and well-being of newborn babies. Lower prevalence of breastfeeding around the globe, rising popularity of nutraceuticals, and low availability of HMOs have inspired efforts to develop economically feasible and efficient industrial-scale production platforms for HMOs. Recent progress in synthetic biology and metabolic engineering tools has enabled microbial systems to be a production system of HMOs. In this regard, the model organism Escherichia coli has emerged as the preferred production platform. Herein, we summarize the remarkable progress in the microbial production of HMOs and discuss the challenges and future opportunities in unraveling the scope of production of complex HMOs. We focus on the microbial production of five HMOs that have been approved for their commercialization.

Keywords

BiotechnologyProduction (economics)NutraceuticalCommercializationScope (computer science)

Identifiers

Journal
Molecules
Year
2023